To observe the clinical study of the safety and efficacy of mouse nerve growth factor for injection in treatment of moderate and severe head trauma.

Totally 60 patients with moderate and severe head trauma in The Affiliated Bayi Brain Hospital, PLA Army General Hospital from February 2012 to December 2015 were included as research subjects. All patients were randomly divided into 30 cases of the observation group and 30 cases of the control group. The control group were received conventional treatment. The observation group were additionally received 30 μg mouse nerve growth factor for injection, once a day, for 3 week, all patients were followed up for 3 months, the GCS, GOS, ADL, MoCA score were recorded before treatment, after 3 weeks treatment and 3 months follow-up, the ICU length of stay, mortality rate were recorded, total clinical efficiency were evaluated.

the GCS, ADL, MoCA score of the observation group and the control group after 3 weeks treatment and follow-up three months were significantly higher than before treatment, F=3.664, 11.827, 9.667 and 3.028, 9.808, 8.623, P<0.05 or P<0.01, and the GCS, ADL, MoCA, GOS score of the observation group after 3 weeks were significantly higher than the control group, t=3.526, 3.665, 3.862, 3.448, all P<0.05, ADL score 3-month follow-up were significantly higher than the control group, t=3.472, P<0.05. the clinical effective rate of the observation group were 86.67%, and the control group were 60%,the difference was significant, χ²=6.393, P<0.05, the ICU stay was not significantly different between both group, t=0.339, P>0.05.

The mouse nerve growth factor for inject have exact efficacy and good security, can quickly promote the recovery of neurological deficit, and also has a positive effect on the consolidated cranial nerve injury, worthy of clinical use.